DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company today announced that IMV Chief Executive Officer Frederic Ors will present at the following investor conferences in May:
RBC Capital Markets Global Healthcare Conference
- Date: Tuesday, May 21, 2019
- Time: 1:35 p.m. ET
- Location: The InterContinental New York Barclay Hotel, New York, NY
National Bank Financials’ 9th Annual Quebec Conference
- Date: Wednesday, May 29, 2019
- Time: 9:50 a.m. ET
- Location: Museum Room, Shangri-la Hotel, Toronto, Ontario
China Bio-Partnering Forum
- Date: Thursday, May 30, 2019
- Time: 1:40 p.m. CT
- Location: Renaissance Schaumburg Convention Center Hotel, Chicago, IL
A copy of each meeting’s presentation will be available in the events and presentations section of IMV’s website. A live webcast of IMV’s presentation at the RBC Capital Markets conference will also be available and archived for 90 days on the events and presentations webpage.
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company’s proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac as a monotherapy in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. Connect at www.imv-inc.com.